Jeff Yass’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.05M | Sell |
38,960
-13,093
| -25% | -$584K | ﹤0.01% | 6425 |
|
|
2026
Q1 | $2.17M | Buy |
52,053
+30,091
| +137% | +$1.23M | ﹤0.01% | 5993 |
|
|
2025
Q4 | $847K | Sell |
21,962
-12,609
| -36% | -$428K | ﹤0.01% | 7555 |
|
|
2025
Q3 | $944K | Buy |
34,571
+23,458
| +211% | +$535K | ﹤0.01% | 7494 |
|
|
2025
Q2 | $215K | Buy |
+11,113
| New | +$202K | ﹤0.01% | 11070 |
|
|
2025
Q1 | – | Sell |
-43,735
| Closed | -$1.05M | – | 12465 |
|
|
2024
Q4 | $1.05M | Sell |
43,735
-2,374
| -5% | -$65.5K | ﹤0.01% | 6834 |
|
|
2024
Q3 | $1.29M | Buy |
46,109
+12,565
| +37% | +$347K | ﹤0.01% | 6246 |
|
|
2024
Q2 | $847K | Buy |
33,544
+21,177
| +171% | +$565K | ﹤0.01% | 6979 |
|
|
2024
Q1 | $360K | Sell |
12,367
-35,485
| -74% | -$973K | ﹤0.01% | 9279 |
|
|
2023
Q4 | $1.17M | Buy |
+47,852
| New | +$944K | ﹤0.01% | 6597 |
|
|
2023
Q3 | – | Sell |
-36,777
| Closed | -$881K | – | 12002 |
|
|
2023
Q2 | $881K | Buy |
36,777
+26,130
| +245% | +$629K | ﹤0.01% | 6993 |
|
|
2023
Q1 | $233K | Sell |
10,647
-25,137
| -70% | -$633K | ﹤0.01% | 10261 |
|
|
2022
Q4 | $894K | Buy |
35,784
+15,501
| +76% | +$386K | ﹤0.01% | 6424 |
|
|
2022
Q3 | $499K | Buy |
+20,283
| New | +$517K | ﹤0.01% | 8493 |
|
|
2022
Q1 | – | Sell |
-9,830
| Closed | -$379K | – | 12963 |
|
|
2021
Q4 | $379K | Buy |
9,830
+1,562
| +19% | +$66.6K | ﹤0.01% | 9917 |
|
|
2021
Q3 | $378K | Sell |
8,268
-5,318
| -39% | -$249K | ﹤0.01% | 10064 |
|
|
2021
Q2 | $678K | Sell |
13,586
-12,103
| -47% | -$592K | ﹤0.01% | 8823 |
|
|
2021
Q1 | $1.32M | Buy |
25,689
+7,933
| +45% | +$434K | ﹤0.01% | 6992 |
|
|
2020
Q4 | $881K | Sell |
17,756
-31,084
| -64% | -$1.4M | ﹤0.01% | 7013 |
|
|
2020
Q3 | $1.9M | Buy |
48,840
+29,457
| +152% | +$1.2M | ﹤0.01% | 4721 |
|
|
2020
Q2 | $837K | Buy |
19,383
+6,099
| +46% | +$233K | ﹤0.01% | 6286 |
|
|
2020
Q1 | $389K | Buy |
13,284
+703
| +6% | +$24.2K | ﹤0.01% | 7465 |
|
|
2019
Q4 | $479K | Buy |
+12,581
| New | +$374K | ﹤0.01% | 7069 |
|
|
2019
Q2 | – | Sell |
-18,990
| Closed | -$541K | – | 10200 |
|
|
2019
Q1 | $541K | Sell |
18,990
-8,568
| -31% | -$224K | ﹤0.01% | 6116 |
|
|
2018
Q4 | $640K | Buy |
27,558
+21,747
| +374% | +$593K | ﹤0.01% | 5547 |
|
|
2018
Q3 | $201K | Buy |
+5,811
| New | +$196K | ﹤0.01% | 8208 |
|
|
2016
Q4 | – | Sell |
-25,119
| Closed | -$569K | – | 9552 |
|
|
2016
Q3 | $569K | Buy |
25,119
+7,300
| +41% | +$150K | ﹤0.01% | 5838 |
|
|
2016
Q2 | $321K | Sell |
17,819
-6,393
| -26% | -$125K | ﹤0.01% | 6841 |
|
|
2016
Q1 | $463K | Sell |
24,212
-8,255
| -25% | -$160K | ﹤0.01% | 6540 |
|
|
2015
Q4 | $943K | Buy |
32,467
+9,523
| +42% | +$275K | ﹤0.01% | 5529 |
|
|
2015
Q3 | $606K | Buy |
+22,944
| New | +$776K | ﹤0.01% | 6736 |
|
Other funds holding BBC
KCP
MCM
QCM
Jeff Yass's BBC Position: Q2 2026 in Review
Jeff Yass reduced its Virtus Biotech Clinical Trials ETF (BBC) stake by 25% in Q2 2026, selling an estimated $584K and leaving 38,960 shares worth $2.05M. The position accounts for ﹤0.01% of the portfolio, ranked #6425.
Jeff Yass first reported a position in BBC in Q3 2015 and has held it in 31 quarters since. The position peaked at $2.17M in Q1 2026. 20 funds tracked by Wall St. Rank hold BBC as of Q2 2026.
- Jeff Yass held 38,960 shares of Virtus Biotech Clinical Trials ETF worth $2.05M as of Q2 2026.
- Jeff Yass sold 13,093 Virtus Biotech Clinical Trials ETF shares in Q2 2026, an estimated $584K.
- Virtus Biotech Clinical Trials ETF made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #6425 holding.
- Jeff Yass first reported a position in Virtus Biotech Clinical Trials ETF in Q3 2015 and has held it in 31 quarters since.
- Jeff Yass's Virtus Biotech Clinical Trials ETF position peaked at $2.17M in Q1 2026.
- 20 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.